Segall Bryant & Hamill LLC Has $12.61 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Segall Bryant & Hamill LLC lowered its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 1.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 153,988 shares of the company’s stock after selling 2,068 shares during the period. Segall Bryant & Hamill LLC’s holdings in Vaxcyte were worth $12,605,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Whipplewood Advisors LLC bought a new position in Vaxcyte in the fourth quarter valued at about $28,000. Smartleaf Asset Management LLC grew its holdings in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after purchasing an additional 260 shares during the last quarter. Blue Trust Inc. increased its position in Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after purchasing an additional 371 shares in the last quarter. Assetmark Inc. lifted its stake in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after purchasing an additional 775 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. acquired a new stake in Vaxcyte in the third quarter valued at approximately $92,000. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Trading Down 2.6 %

Shares of PCVX stock opened at $71.90 on Wednesday. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06. The stock has a market cap of $9.26 billion, a price-to-earnings ratio of -15.63 and a beta of 1.02. The stock has a 50-day moving average of $81.14 and a 200-day moving average of $93.33.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. Sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Wall Street Analyst Weigh In

PCVX has been the subject of several research analyst reports. Guggenheim reiterated a “buy” rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $147.50.

Insider Transactions at Vaxcyte

In other news, Director Teri Loxam sold 6,250 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares of the company’s stock, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the transaction, the chief operating officer now owns 205,695 shares in the company, valued at $17,208,443.70. The trade was a 3.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 46,250 shares of company stock worth $3,840,018 over the last three months. 3.10% of the stock is owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.